Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations

被引：2
|
作者：
不详
机构：
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 01期
关键词：
D O I：
10.1016/j.jtho.2022.10.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E3 / E4
页数：2
相关论文
共 50 条
  • [1] Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations
    Zhao, Binghao
    Xing, Hao
    Ma, Wenbin
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : E76 - E77
  • [2] Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
    Kenmotsu, Hirotsugu
    Wakuda, Kazushige
    Mori, Keita
    Kato, Terufumi
    Sugawara, Shunichi
    Kirita, Keisuke
    Yoneshima, Yasuto
    Azuma, Koichi
    Nishino, Kazumi
    Teraoka, Shunsuke
    Shukuya, Takehito
    Masuda, Ken
    Hayashi, Hidetoshi
    Toyozawa, Ryo
    Miura, Satoru
    Fujimoto, Daichi
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : 1098 - 1108
  • [3] Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
    Kenmotsu, Hirotsugu
    Sakai, Kazuko
    Mori, Keita
    Kato, Terufumi
    Sugawara, Shunichi
    Kirita, Keisuke
    Yoneshima, Yasuto
    Azuma, Koichi
    Nishino, Kazumi
    Teraoka, Shunsuke
    Koyama, Ryo
    Masuda, Ken
    Hayashi, Hidetoshi
    Toyozawa, Ryo
    Miura, Satoru
    Sato, Yuki
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Nishio, Kazuto
    Takahashi, Toshiaki
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (11):
  • [4] Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis
    Zhou, Guojin
    Guo, Liuxian
    Xu, Jing
    Tang, Kejing
    Chen, Jie
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [5] Savolitinib Plus Osimertinib for Previously Untreated NSCLC Patients with EGFR Mutations and MetAmplification: A Case Series
    Xiao, K.
    Chu, T.
    Zhu, Y.
    Yang, S.
    Xiao, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S637 - S637
  • [6] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [7] FLAIR: Phase II Study of Osimertinib plus Bevacizumab versus Osimertinib in Advanced NSCLC Patients with EGFR L858R Mutation
    Zhou, Q.
    Xu, C.
    Chen, H.
    Tu, H.
    Wang, B.
    Yan, H.
    Zhang, X.
    Yang, J.
    Zhong, W.
    Liu, S.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S613 - S613
  • [8] Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
    Xiaoyang Zhai
    Wanhu Li
    Ji Li
    Wenxiao Jia
    Wang Jing
    Yaru Tian
    Shuhui Xu
    Yuying Li
    Hui Zhu
    Jinming Yu
    Radiation Oncology, 16
  • [9] Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study
    Zhai, Xiaoyang
    Li, Wanhu
    Li, Ji
    Jia, Wenxiao
    Jing, Wang
    Tian, Yaru
    Xu, Shuhui
    Li, Yuying
    Zhu, Hui
    Yu, Jinming
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [10] Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study
    Kenmotsu, H.
    Wakuda, K.
    Mori, K.
    Kato, T.
    Sugawara, S.
    Kirita, K.
    Okamoto, I.
    Azuma, K.
    Nishino, K.
    Teraoka, S.
    Koyama, R.
    Masuda, K.
    Hayashi, H.
    Toyozawa, R.
    Miura, S.
    Sato, Y.
    Nakagawa, K.
    Yamamoto, N.
    Takahashi, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1322 - S1323
12345